GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Osiris Therapeutics Inc (NAS:OSIR) » Definitions » Net Cash per Share

Osiris Therapeutics (Osiris Therapeutics) Net Cash per Share : $0.05 (As of Dec. 2018)


View and export this data going back to 2006. Start your Free Trial

What is Osiris Therapeutics Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Osiris Therapeutics's Net Cash per Share for the quarter that ended in Dec. 2018 was $0.05.

The historical rank and industry rank for Osiris Therapeutics's Net Cash per Share or its related term are showing as below:

OSIR's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 4.165
* Ranked among companies with meaningful Price-to-Net-Cash only.

Osiris Therapeutics Net Cash per Share Historical Data

The historical data trend for Osiris Therapeutics's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Osiris Therapeutics Net Cash per Share Chart

Osiris Therapeutics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.09 -0.09 -0.37 -0.26 0.05

Osiris Therapeutics Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.26 -0.34 -0.17 0.04 0.05

Competitive Comparison of Osiris Therapeutics's Net Cash per Share

For the Biotechnology subindustry, Osiris Therapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Osiris Therapeutics's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Osiris Therapeutics's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Osiris Therapeutics's Price-to-Net-Cash falls into.



Osiris Therapeutics Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Osiris Therapeutics's Net Cash per Share for the fiscal year that ended in Dec. 2018 is calculated as

Net Cash per Share (A: Dec. 2018 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(24.643-22.974-0)/34.527
=0.05

Osiris Therapeutics's Net Cash per Share for the quarter that ended in Dec. 2018 is calculated as

Net Cash per Share (Q: Dec. 2018 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(24.643-22.974-0)/34.527
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Osiris Therapeutics  (NAS:OSIR) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Osiris Therapeutics Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Osiris Therapeutics's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Osiris Therapeutics (Osiris Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
7015 Albert Einstein Drive, Columbia, MD, USA, 21046-1707
Osiris Therapeutics is a biotechnology company involved in researching, developing, and marketing cellular regenerative medicine products. The company's therapeutic areas focus on innovation in regenerative medicine, including bioengineering, stem cell research, and viable tissue-based products. Osiris has accomplished commercial success with products in orthopedics, sports medicine, and wound care, such as Cartiform, Ovation, and Grafix.
Executives
Reinhart Charles A. Iii director C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Linda L Chang officer: Chief Financial Officer ONE PARK PLACE, STE 450, ANNAPOLIS MD 21401
Shauna L Vernal officer: Chiel Legal Officer
Linda Palczuk officer: President & CEO 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046
David L White director
Thomas J Knapp director 4640 SW MACADAM AVE., SUITE 270, PORTLAND OR 97239
Jonathan Mark Hopper officer: Chief Medical Officer 64 SIDNEY STREET, CAMBRIDGE MA 02139
Jacoby Philip R Jr officer: Principal Accounting Officer
C Randal Mills director, officer: President & CEO 18366 CALLE STELLINA, RANCHO SANTA FE CA 92091
Jay M Moyes director
Stephen W Potter officer: Senior Vice President 7015 ALBERT EINSTEIN DR, COLUMBIA MD 21046
Gregory Hurd Barnhill director

Osiris Therapeutics (Osiris Therapeutics) Headlines

From GuruFocus